EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-dose intraperitoneal rAd/p53 gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival



Multi-dose intraperitoneal rAd/p53 gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival



Cancer Gene Therapy 7(12): S1, December




(PDF 0-2 workdays service: $29.90)

Accession: 035349134

Download citation: RISBibTeXText



Related references

Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer. Tumori 96(6): 918-925, 2011

Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Annals of Surgical Oncology 19(7): 2352-2359, 2012

HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. International Journal of Cancer 136(3): 699-708, 2015

Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology 71(2): 190-195, 1998

Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Annals of Surgical Oncology 21(11): 3621-3627, 2015

Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology 23(5): 1660-1665, 2015

Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report. Journal of Obstetrics and Gynaecology Research, 2017

Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 79(1-2): 98-104, 2011

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. Journal of Ovarian Research 5(1), 2012

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. Journal of Ovarian Research 5(1): 17-17, 2012

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer. Cancer Research and Treatment 45(1): 40-47, 2013

Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. Oncology Reports 3(5): 947-949, 1996

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics & Gynecology Science 61(3): 352-358, 2018

Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Journal of Korean Medical Science 24(5): 945-950, 2010

Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. Current Protein & Peptide Science 16(4): 329-336, 2016